About EnPlusOne Bio
EnPlusOne Bio is a company based in Watertown (United States) founded in 2022 by Daniel Wiegand, Jonathan Rittichier, Daniel Ahlstedt, Howon Lee, and George M Church. EnPlusOne Bio has raised $46.71 million across 3 funding rounds from investors including Northpond Ventures, Breakout Ventures and Coatue. EnPlusOne Bio offers products and services including Solutions. EnPlusOne Bio operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Watertown, United States
- Founders Daniel Wiegand, Jonathan Rittichier, Daniel Ahlstedt, Howon Lee, George M Church
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$46.71 M (USD)
in 3 rounds
-
Latest Funding Round
$21.82 M (USD), Series B
Dec 09, 2024
-
Investors
Northpond Ventures
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of EnPlusOne Bio
EnPlusOne Bio offers a comprehensive portfolio of products and services, including Solutions.
Provides enzyme-based innovations for RNA delivery and therapeutics.
People of EnPlusOne Bio
Unlock access to complete
Unlock access to complete
Funding Insights of EnPlusOne Bio
EnPlusOne Bio has successfully raised a total of $46.71M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $21.82 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in EnPlusOne Bio
EnPlusOne Bio has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Northpond Ventures, Breakout Ventures and Coatue.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life sciences & tech sectors
|
Locked | Locked | Locked | |
|
Early-stage investments in science-driven companies are made.
|
Locked | Locked | Locked | |
|
Provider of an investment platform for various stages
|
Locked | Locked | Locked |
Investor details for EnPlusOne Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by EnPlusOne Bio
Investment portfolio details for EnPlusOne Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - EnPlusOne Bio
Detailed financials for EnPlusOne Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Enplusone Bio Comparisons
Peer comparison for EnPlusOne Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of EnPlusOne Bio
EnPlusOne Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of EnPlusOne Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Enplusone Bio
Complete news archive for EnPlusOne Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EnPlusOne Bio
EnPlusOne Bio was founded in 2022.
EnPlusOne Bio is headquartered in Watertown, United States.
Daniel Wiegand is the current CEO of EnPlusOne Bio. They have also founded this company.
EnPlusOne Bio is a funded company, having raised a total of $46.71M across 3 funding rounds to date.
EnPlusOne Bio was founded in 2022 and is based in Watertown, United States. An RNA synthesis platform known as ezRNA is developed by the company within the biotechnology sector. This platform enables enzymatic production of RNA therapeutics incorporating diverse nucleotide modifications. Operations focus on advancing gene therapy applications through scalable synthesis methods.
EnPlusOne Bio's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
EnPlusOne Bio offers Solutions.
EnPlusOne Bio has 3 investors. Key investors include Northpond Ventures, Breakout Ventures, and Coatue.